Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects are being tested with QRX003 as monotherapy.
Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is anticipated to provide QRX003 with the broadest possible label opportunity post-approval as both monotherapy and adjunct therapy in conjunction with off-label systemic treatments.
Five U.S. clinical sites have been opened, and six international sites are being opened. All currently have available cohorts of subjects ready to be enrolled into the studies facilitating accelerated recruitment.
Quoin anticipates completion of recruitment into both pivotal studies by end of Q1 2026 and filing an NDA for regulatory approval later in the year.
ASHBURN, Va., May 22, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the 'Company' or 'Quoin'), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a second Netherton Syndrome (NS) pivotal clinical study CL-QRX003-002 for QRX003. Quoin's lead product, QRX003, is a topical lotion formulated with a broad-spectrum serine protease inhibitor that has been shown to significantly downregulate the hyperactivity of the kallikreins in the skin responsible for the excessive skin shedding associated with this disease. Clinical data from Quoin's ongoing studies has demonstrated clear evidence of rapid, prolonged and almost complete skin healing following twice-daily application of QRX003 to the treatment areas along with the almost complete elimination of key symptoms such as chronic, debilitating pruritus and has facilitated zero nightly sleep disturbances.
Study CL-QRX003-002 builds off of positive clinical data generated in Quoin's earlier stage open-label study where QRX003 was applied to the arms and lower legs or approximately 20% of each subject's body surface area (BSA). In this pivotal study, QRX003 will be applied to approximately 12-15 subjects twice daily to at least 80% of each of the subjects' BSA thereby generating substantially more safety and efficacy data per subject and will match how QRX003 is intended to be used if regulatory approval is obtained. All subjects recruited into this study are currently receiving off-label systemic therapy and will continue to remain on this treatment for the duration of the study. Study CL-QRX003-002 complements Quoin's other pivotal study, CL-QRX003-003, which is being conducted by Dr. Amy Paller, of Northwestern University, where QRX003 is being administered as monotherapy and subjects do not receive off-label systemic therapy. Quoin anticipates that combined both studies will recruit between 24-30 subjects in 6 U.S. sites and up to 6 international sites. Five of the U.S. sites are already open and the sixth is expected to be opened in June. All international sites are at an advanced stage of preparation for opening. Each of the U.S. and international sites has available cohorts of subjects that are ready to participate in both studies facilitating a rapid pace of recruitment which could enable Quoin to achieve its target of fully completing recruitment before the end of Q1 2026 and to file an NDA for regulatory approval later in the year.
Quoin CEO, Dr. Michael Myers, added, 'I am very pleased to announce yet another important and significant milestone for Quoin. With FDA clearance to conduct this study, Quoin is the only company conducting two late-stage whole-body pivotal clinical studies in Netherton Syndrome patients. We believe that the combined data generated from Study CL-QRX003-003, where QRX003 is being administered as monotherapy and this study, CL-QRX003-002, where QRX003 is being tested in conjunction with off-label systemic therapy, has the potential to generate a highly comprehensive safety and efficacy data package that could support the regulatory approval of a treatment for this dreadful disease.'
About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking StatementsThe Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'look forward to,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: study CL-QRX003-002 testing the whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects, six international sites opening to support study CL-QRX003-003 testing subjects with QRX003 as monotherapy, combined data from Studies CL-QRX0003-002 and CL-QRX003 providing QRX003 with the broadest possible label opportunity post-approval as both monotherapy and adjunct therapy in conjunction with off-label systemic treatments, available cohorts of subjects being ready to be enrolled into the studies facilitating accelerated recruitment at the clinical sites, completing recruitment into both pivotal studies by end of Q1 2026, filing an NDA for regulatory approval later in the year, combined both studies recruiting between 24-30 subjects in 6 US sites and up to 6 international sites, opening a sixth US site in June, and Quoin's belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to pursue its regulatory strategy; the Company's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company's ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.Michael Myers, Ph.D., CEOmmyers@quoinpharma.com
Investor RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com(646) 863-6341
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
VitaMotion Introduced in 2025 as Your Healthy Back Protocol for Mobility and Comfort Support
New York, Aug. 13, 2025 (GLOBE NEWSWIRE) — Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). VitaMotion is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. VitaMotion Launches Dual-Action Mobility and Back Health System for 2025 Wellness Demands Summary VitaMotion introduces a two-step program combining a nutrient-rich daily formula with a guided mobility routine developed by kinesiologist Rick Kaselj. The system is designed to address back, joint, and muscle health from both an internal and external perspective. Mobility and Back Health – A Public Health Priority Back, joint, and mobility concerns are now recognized as some of the most widespread health challenges globally. The World Health Organization reports that musculoskeletal conditions affect an estimated 1.71 billion people worldwide, making them the leading contributor to disability. The Centers for Disease Control and Prevention (CDC) estimates that one in four U.S. adults experiences chronic joint symptoms, while lower back pain consistently ranks as one of the top causes of missed workdays. The economic burden is equally significant. According to data from the Global Burden of Disease Study, musculoskeletal disorders account for hundreds of billions of dollars in healthcare costs and productivity losses annually. In workplace environments, prolonged sitting, inadequate movement breaks, and poor ergonomic setups have all been identified as contributing factors to rising cases of posture-related discomfort and reduced range of motion. This growing public health issue extends across all age groups. Aging adults face natural declines in muscle mass, bone density, and joint lubrication, but younger populations are also affected due to sedentary lifestyles. Research from the Arthritis Foundation notes that early intervention through movement and targeted nutrition can play a key role in maintaining long-term mobility. Learn more about the VitaMotion Mobility & Back Health System here Rick Kaselj – Professional Background and Expertise Rick Kaselj, MS, BSc, has dedicated over 30 years to developing safe and effective mobility solutions. With a Bachelor's degree in Kinesiology from Simon Fraser University and a Master's in Exercise Science from California University of Pennsylvania, Kaselj has delivered over 315 live presentations to health and fitness professionals across North America. Throughout his career, he has specialized in bridging the gap between injury rehabilitation and functional movement. His previous work, including the widely recognized Unlock Your Hip Flexors program, has reached hundreds of thousands of people worldwide. For VitaMotion, Kaselj applied these same principles to design a concise daily mobility sequence that is adaptable for all fitness levels, requires no special equipment, and fits into a variety of environments. The Two-Step VitaMotion System VitaMotion is built around two coordinated components: Step 1 – Nutritional Support The daily powdered supplement contains nine active ingredients: magnesium, vitamin B complex, vitamin D, curcumin (from turmeric), boswellia serrata, ginger, white willow bark, L-theanine, and alpha lipoic acid. Each nutrient was selected for its documented role in supporting muscle, joint, and nerve function. Formulated without artificial fillers, dyes, or unnecessary additives, the blend is designed to be mixed with water and taken once daily, ideally in the morning when nutrient absorption can be most efficient. Step 2 – Guided Mobility Routine The 7–10 minute mobility sequence uses a 'release outer muscles first' approach. By easing surface-level muscle tension before activating deeper stabilizers, the sequence helps encourage improved alignment, posture, and range of motion. Movements are low-impact and can be performed either standing or seated, making the program accessible for individuals with varying mobility levels. Ingredient Science and Supporting Research Magnesium Essential for muscle contraction and relaxation, magnesium supports nerve signaling and energy metabolism. The USDA has reported that low magnesium intake increases muscle fatigue and effort perception during activity. Harvard Health notes its role in flexibility and tension reduction. Vitamin B Complex Comprising eight essential vitamins, the B complex contributes to energy production and neuromuscular coordination. The Linus Pauling Institute highlights its importance in sustaining nerve health and physical endurance. Vitamin D Supports muscle performance, bone density, and balance. The NIH reports that adequate vitamin D levels can contribute to improved spine mobility and reduced risk of falls among older adults. Curcumin A bioactive compound in turmeric, curcumin has been studied for its role in supporting a healthy inflammatory response. A 2018 review in Frontiers in Pharmacology discusses its potential in maintaining mobility and joint comfort. Boswellia Serrata Traditionally used to promote joint flexibility, boswellia has been examined for its capacity to support smooth movement and overall comfort. Memorial Sloan Kettering Cancer Center provides a comprehensive overview of its uses. Ginger Recognized for supporting circulation and potentially aiding in muscle performance after activity, ginger's active compounds have been the focus of both culinary and medical research. White Willow Bark Historically valued for promoting everyday comfort, white willow bark's traditional uses are well-documented in herbal medicine literature and supported by multiple small-scale studies. L-Theanine An amino acid naturally found in tea leaves, L-theanine supports a calm, focused state, potentially aiding natural muscle relaxation without sedation. Alpha Lipoic Acid A versatile antioxidant, alpha lipoic acid supports nerve health, energy metabolism, and cellular resilience against oxidative stress. View the full ingredient profile and program details for VitaMotion here Why Movement and Nutrition Work Better Together Multiple studies across sports medicine, gerontology, and rehabilitation science point to the benefits of combining physical activity with targeted nutritional support. Research published in the Journal of Aging Research (2023) concluded that daily low-impact movement, when paired with specific micronutrients, can help maintain independence and functional ability in older adults. Movement stimulates blood flow, improving the delivery of nutrients to muscles and joints. At the same time, nutrients like magnesium, vitamin D, and antioxidants support the very systems that movement relies on — from neuromuscular signaling to collagen synthesis and inflammatory balance. This cyclical reinforcement may explain why integrated programs are increasingly recommended in preventive care models. Market Growth and Consumer Trends The joint health supplement industry was valued at over $11 billion in 2024, according to Grand View Research, with projections showing continued growth through 2030. The home fitness and wellness program market has followed a similar trajectory, driven by demand for convenient, adaptable solutions. Social media analytics show that hashtags such as #MobilityExercises and #BackPainRelief have collectively reached billions of views across TikTok and Instagram. Reddit communities focused on flexibility, functional training, and posture correction have seen consistent subscriber growth, with many users discussing the benefits of combining movement routines with nutritional strategies. Industry analysts anticipate that corporate wellness initiatives will increasingly integrate programs similar to VitaMotion, particularly as employers look to reduce costs associated with absenteeism and musculoskeletal claims. Lifestyle Integration VitaMotion was designed for versatility. Examples of integration include: Workplace Wellness : Employees can complete the seated mobility sequence during short breaks, helping offset the effects of prolonged sitting. : Employees can complete the seated mobility sequence during short breaks, helping offset the effects of prolonged sitting. Travel : The supplement can be packed in single-serve packets, and the routine can be done in hotel rooms without equipment. : The supplement can be packed in single-serve packets, and the routine can be done in hotel rooms without equipment. Home Use : Fits easily between household tasks or before leisure activities. : Fits easily between household tasks or before leisure activities. Active Aging : Older adults can adapt the movements to their comfort level, maintaining independence and confidence in daily activities. : Older adults can adapt the movements to their comfort level, maintaining independence and confidence in daily activities. Sports and Recreation: Athletes or hobbyists can use the sequence as a gentle warm-up or recovery tool. Observations from Public Data An analysis of online discussions and publicly available feedback on integrated mobility systems shows recurring themes: users are often drawn to programs that are time-efficient, require minimal space or equipment, and are supported by transparent ingredient information. Search trends indicate that consumers are more likely to adopt systems that combine educational content with practical, easy-to-follow routines. Industry reports also highlight a shift toward preventive mobility care, with growing interest in tools that address both the underlying physical structures and the nutritional factors influencing them. Future Outlook As wearable technology, AI-driven movement analysis, and ingredient traceability continue to advance, integrated systems like VitaMotion are expected to become even more personalized. Future iterations of such programs may include real-time posture correction, adaptive exercise progressions, and customized nutrient blends based on individual biomarker data. Public health experts anticipate that the convergence of these technologies with established exercise and nutrition science could set new standards for preventive musculoskeletal care worldwide. Contact VitaMotion – Healthy Back Protocol – Healthy Back Protocol Email: [email protected] Disclaimer: This release is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Statements have not been evaluated by the Food and Drug Administration. VitaMotion is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before starting any new supplement or movement program. Some links may lead to third-party sites. The publisher or author may receive compensation from purchases made through these links, at no extra cost to the buyer. This does not influence the content provided. Results vary. References to ingredients are based on public discussion and historical use and are not endorsements by medical professionals or regulatory agencies. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
4 hours ago
- Business Upturn
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the 'Class Period'), of the important September 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Centene securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Centene class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning Centene's expected revenue guidance and adjusted diluted earnings per share ('EPS') for the 2025 fiscal year. Defendants' statements included, among other things, confidence in Centene's enrollment and morbidity rates, as well as strong retention rates in Centene's Medicare business. Defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Centene class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Business Upturn
4 hours ago
- Business Upturn
ROK Financial Expands Merchant Cash Advance and Working Capital Programs to Deliver Same-Day Business Funding Nationwide
New York, Aug. 13, 2025 (GLOBE NEWSWIRE) — ROK Financial Expands Merchant Cash Advance, Working Capital, and Fast Small Business Loan Programs to Deliver Same-Day Business Funding Nationwide ROK Financial, a leading provider of small business financing solutions, has expanded its Merchant Cash Advance, Working Capital, and alternative business loan programs to give business owners faster, more flexible access to capital. Designed for the more than 33 million small businesses operating across the United States — which collectively employ nearly half of the U.S. workforce — these solutions meet the needs of industries as diverse as retail, construction, e-commerce, logistics, healthcare, hospitality, trades, and professional services. For many small businesses, access to traditional bank loans has become increasingly difficult due to strict collateral requirements, high credit score minimums, and long approval times. ROK Financial's programs address these barriers by providing same-day funding from $10,000 to $5 million, with repayment structures that adjust to match cash flow. Programs are available to companies with as little as four months in operation and require no minimum credit score, opening doors for entrepreneurs who may not qualify for traditional lending. Business owners can learn more or begin the application process by visiting ROK Financial's official funding page. The Need for Speed in Small Business Financing The ability to access capital quickly can determine whether a small business seizes a growth opportunity or struggles to cover operational expenses. According to the Federal Reserve, nearly half of small businesses report they would need to find funding within a month or less to manage an unexpected expense. For many owners, traditional bank lending is too slow, requiring weeks of underwriting, extensive documentation, and high credit thresholds. Merchant Cash Advance and Working Capital programs address these challenges by providing fast, flexible business financing that moves at the pace of modern commerce. Same-day approval and funding in as little as a few hours mean that a retail store can order last-minute holiday inventory, a construction company can purchase materials to start a new project immediately, or a restaurant can repair critical kitchen equipment without losing valuable service days. This speed is not only critical for growth but also for business continuity. In the event of equipment breakdowns, supply chain disruptions, or emergency facility repairs, immediate access to funding can mean the difference between staying operational and losing valuable revenue days. Seasonal businesses — such as landscaping companies, tax preparation services, and tourism operators — can also benefit by securing capital ahead of their busiest months to maximize earnings potential. Learn more about how these programs work by visiting ROK Financial's Merchant Cash Advance information page. How Merchant Cash Advance and Working Capital Solutions Work A Merchant Cash Advance is not a traditional loan with fixed monthly payments. Instead, it provides a lump sum of working capital in exchange for a percentage of a business's future credit card sales or daily bank deposits. Payments automatically adjust with revenue — higher in busy months, lower when business is slower — making it a flexible solution for managing seasonal cash flow. Unlike bank loans, Merchant Cash Advances do not require collateral, lengthy approval processes, or high credit scores. Working Capital loans function in a similar way, providing fast access to funds that can be used for virtually any business purpose. This could mean financing a marketing campaign to attract new customers, purchasing equipment to expand production, upgrading technology systems to improve efficiency, or covering payroll during a temporary cash flow gap. Compared to other financing methods, MCA and Working Capital programs often have shorter application timelines, fewer documentation requirements, and repayment schedules tied to sales performance. For business owners seeking agility, these solutions act as a bridge between cash flow needs and growth objectives without the rigid repayment structures common in conventional lending. Get started today with ROK Financial's pre-approval application. Flexible Funding from $10,000 to $5 Million ROK Financial's Merchant Cash Advance and Working Capital programs offer funding amounts ranging from $10,000 to $5 million, making them accessible to both small, growing businesses and established companies with larger capital needs. Smaller funding packages can bridge short-term cash flow gaps, cover urgent repairs, or fund seasonal staffing increases. Larger packages can support major investments such as opening new locations, launching large-scale marketing campaigns, purchasing advanced machinery, or securing bulk inventory at discounted rates. Examples of funding use include: A restaurant replacing a commercial oven to avoid service disruption. A construction company purchasing heavy machinery for a large project. A retail store stocking up on seasonal inventory ahead of a major holiday. An e-commerce brand investing in a national digital advertising campaign. A manufacturer upgrading its production line for increased capacity. The flexibility of these programs is especially valuable to industries with fluctuating revenue patterns. For example, a tourism business may require significant working capital ahead of its high season to invest in marketing and staffing, while an agricultural supplier may need immediate funds to secure seeds, fertilizer, and equipment before planting season begins. Three-Step Application Process ROK Financial has simplified the process of securing business funding into three clear steps: Step 1: Complete a secure online application in just a few seconds. Applicants provide essential details about their business, including revenue, time in operation, and industry type. This quick submission is designed to match business owners with the most relevant financing options without requiring extensive initial documentation. Step 2: Connect with a dedicated financing advisor who reviews available programs and presents personalized funding solutions. This consultation ensures business owners understand their options, repayment structures, and terms before making a decision. Step 3: Select the preferred offer and receive funds in as little as 24 hours. There is no obligation to accept an offer, allowing owners to compare options and choose the best fit for their needs. This streamlined approach eliminates unnecessary delays and allows entrepreneurs to focus on running their businesses while securing the capital they need. Qualification Made Simple ROK Financial's Merchant Cash Advance and Working Capital programs are designed with accessibility in mind. Businesses with as little as four months in operation can apply, provided they generate at least $10,000 in monthly gross sales. There is no minimum FICO score required, making these programs available to owners with strong sales performance but limited or imperfect credit history. This flexibility opens the door for restaurants with steady daily sales but no collateral, retail shops in their first year of operation, service-based businesses with seasonal income, and contractors who rely on fluctuating project schedules. By focusing on current business performance rather than rigid credit requirements, ROK Financial ensures that more entrepreneurs have a pathway to the funding they need. Proof Points: Market Trends in Alternative Business Financing Alternative financing options such as Merchant Cash Advances and Working Capital loans have become increasingly popular as small businesses seek faster, more flexible ways to secure capital. Industry research shows that the U.S. alternative lending market is projected to grow steadily through the decade, driven by demand for quick approvals, adaptable repayment terms, and less restrictive qualification criteria. For many entrepreneurs, the appeal lies in bypassing the traditional bank loan process, which often involves weeks of review, strict collateral requirements, and high credit score thresholds. Instead, programs like those offered by ROK Financial prioritize revenue performance, making them accessible to a wider range of businesses. As competition across industries intensifies, having rapid access to funding can be a decisive factor in capturing market opportunities. Social Impact Commitment ROK Financial is committed not only to supporting business growth but also to making a positive impact in the community. Through its ongoing partnership with Feeding America, the company has provided more than one million meals to families in need. For every successful funding transaction, ROK Financial donates 50 meals to help fight food insecurity in communities across the United States. This initiative reflects the company's belief that business success and social responsibility go hand in hand. By choosing ROK Financial for their Merchant Cash Advance or Working Capital needs, business owners are also contributing to a broader mission of helping families and strengthening local communities. Frequently Asked Questions What is the difference between a Merchant Cash Advance and a traditional loan? A Merchant Cash Advance is repaid as a percentage of future sales, which means repayment amounts vary based on revenue. Traditional loans have fixed monthly payments regardless of sales volume. Can I get business funding with bad credit? Yes. There is no minimum credit score required for ROK Financial's Merchant Cash Advance or Working Capital programs. Approval is based primarily on business performance, including revenue and time in operation. How quickly can I receive funding? In many cases, qualified businesses can receive funds the same day they apply, depending on application time and the submission of required information. What types of businesses qualify? These programs are available to a wide variety of industries, including restaurants, retail, construction, manufacturing, e-commerce, logistics, healthcare, hospitality, and more. Can funds be used for any purpose? Yes. Working capital can be used for expenses such as payroll, inventory, marketing, equipment upgrades, expansion initiatives, or emergency operational needs. How does repayment work for a Merchant Cash Advance? Repayment is made automatically by deducting a fixed percentage of your daily or weekly sales until the advance is fully repaid. This means payments are proportionate to revenue, offering flexibility during slower months. Is there a penalty for early repayment? Many MCA and Working Capital programs have no prepayment penalties, allowing business owners to pay off their balance early if they choose. Terms vary by agreement, so applicants should confirm details with their financing advisor. Can start-ups apply? Yes, businesses with at least four months in operation can qualify, making these programs suitable for newer companies seeking to build momentum. Do I need to offer collateral? No. Merchant Cash Advances and Working Capital programs offered by ROK Financial do not require physical collateral, making them an option for businesses without significant assets. About ROK Financial ROK Financial is a business financing provider based in Great River, New York. The company specializes in delivering fast, flexible funding solutions tailored to the needs of small and medium-sized businesses across multiple industries. Using a technology-first approach, ROK Financial streamlines the funding process while maintaining a strong focus on customer service. The company's suite of financing products includes Merchant Cash Advance, Working Capital Loans, business lines of credit, equipment financing, SBA loans, and more. Contact Information ROK Financial Phone: (833) 3-ROKBIZ (833) 3-ROKBIZ Email: [email protected] [email protected] Website: Office Hours: Monday – Saturday, 8:00 A.M. – 6:00 P.M. (EST) Disclaimer: The information provided in this release is for informational purposes only and does not constitute financial advice. Funding availability, terms, and conditions are subject to change based on applicant eligibility and underwriting review. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
